Sign In
Buy SELB
$0.88
+0 (+0%)
At Close: Feb 12, 2024
Selecta Biosciences Stock Is Trading Lower After Gaining Total Rights To MMA Program From AskBio
10:52am, Thursday, 29'th Apr 2021
Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosc
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
08:30am, Thursday, 29'th Apr 2021
– Methylmalonic Acidemia (MMA) program to become wholly-owned by Selecta –
Selecta: ImmTOR Promises A Therapeutic Revolution, But SEL-212 May Dash Hopes
12:53am, Wednesday, 31'st Mar 2021
Selecta: ImmTOR Promises A Therapeutic Revolution, But SEL-212 May Dash Hopes
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2020 Results - Earnings Call Transcript
02:37pm, Thursday, 11'th Mar 2021
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2020 Results - Earnings Call Transcript
Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates
10:37am, Thursday, 11'th Mar 2021
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 6.67% and 105.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the
WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic the
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
08:00am, Monday, 01'st Mar 2021
WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic the
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
04:15pm, Wednesday, 24'th Feb 2021
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector -
Why Novartis, Seelos Therapeutics And More Are Moving Today
11:52am, Tuesday, 26'th Jan 2021
Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based
- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8 al
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
08:00am, Monday, 04'th Jan 2021
WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ther
Selecta: ImmTOR Platform's Potential In Key
04:49am, Friday, 25'th Dec 2020
Selecta was down due to unclear results from the COMPARE trial. Management attributes poor data to noncompliance due to covid-19, among other things.
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript
05:47am, Saturday, 07'th Nov 2020
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
07:30am, Thursday, 05'th Nov 2020
WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic th
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights
08:00am, Thursday, 29'th Oct 2020
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies base
